Ellagic acid mitigates sodium arsenite-induced renal and hepatic toxicity in male Wistar rats

The aim of this study was to investigate the effect of ellagic acid (EA) on arsenic-induced renal and hepatic toxicity in rats. A total number of 35 male Wistar rats were randomly divided into five experimental groups. Group 1 received normal saline (po). Group 2 received sodium arsenite (SA, 10mg/k...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacological reports 2018-08, Vol.70 (4), p.712-719
Main Authors: Mehrzadi, Saeed, Fatemi, Iman, Malayeri, Ali Reza, Khodadadi, Ali, Mohammadi, Fatemeh, Mansouri, Esrafil, Rashno, Mohammad, Goudarzi, Mehdi
Format: Article
Language:English
Subjects:
Alanine Transaminase
Alkaline Phosphatase - metabolism
Animals
Arsenites
Aspartate Aminotransferases - metabolism
Biomarkers - blood
Biomarkers - metabolism
Blood Urea Nitrogen
Chemical and Drug Induced Liver Injury - blood
Chemical and Drug Induced Liver Injury - metabolism
Chemical and Drug Induced Liver Injury - pathology
Chemical and Drug Induced Liver Injury - prevention & control
Creatinine - blood
Dose-Response Relationship, Drug
Drug Safety and Pharmacovigilance
Ellagic acid
Ellagic Acid - pharmacology
Glutathione - metabolism
Glutathione Peroxidase - metabolism
Kidney Diseases - chemically induced
Kidney Diseases - metabolism
Kidney Diseases - pathology
Kidney Diseases - prevention & control
Male
Malondialdehyde - metabolism
Nitric Oxide - metabolism
Original Article
Oxidative stress
Pharmacotherapy
Pharmacy
Rats
Sodium arsenite
Sodium Compounds
Superoxide Dismutase - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study was to investigate the effect of ellagic acid (EA) on arsenic-induced renal and hepatic toxicity in rats. A total number of 35 male Wistar rats were randomly divided into five experimental groups. Group 1 received normal saline (po). Group 2 received sodium arsenite (SA, 10mg/kg, po) for 21days. Group 3 received EA (30mg/kg, po) for 14days. Groups 4 and 5 received SA 7days prior to EA (10 and 30mg/kg respectively) treatment and continued up to 21days simultaneous with SA administration. Various biochemical, histological and molecular biomarkers were measured in kidney and liver. Treatment with EA (more potently at dose of 30mg/kg) restored the SA-induced alterations in serum creatinine (Cr) and blood urine nitrogen (BUN) levels as well as the changes in aspartate aminotransferase (AST), alkaline phosphatase (ALP) and alanine aminotransferase (ALT) concentrations (all p
ISSN:1734-1140
2299-5684
DOI:10.1016/j.pharep.2018.02.007